×

Indications

Prolia® is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal Read More

Prolia® is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Prolia® reduces the incidence of vertebral, nonvertebral, and hip fractures.

Prolia® is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

Prolia® is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer. In these patients Prolia® also reduced the incidence of vertebral fractures.

Prolia® is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. Close

Prolia® is the only FDA-approved therapy for cancer treatment–induced bone loss (CTIBL) due to hormone ablation therapy (CTIBL-HALT).1


Prolia® can help protect bone health for your breast cancer patients on aromatase inhibitor (AI) therapy at high risk for fracture.1

Indication: Prolia® is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.

RISK EVALUATION AND MITIGATION STRATEGY (REMS)

Learn about co-pay and reimbursement resources for your Prolia® CTIBL-HALT patients.

AI therapy results in estrogen depletion, leading to lower bone mineral density (BMD) and increased fracture risk2

Learn about results from studies of bone loss at the lumbar spine and incidence rate of fracture among patients with breast cancer on AI therapy.

Increase BMD in breast cancer patients on AI therapy1,3

Fracture reduction data now available in nonmetastatic breast cancer patients on AI therapy2

Prolia® is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.

Prolia® is
1 Shot Every
6
Months1

Single-use
prefilled 1 mL syringe

  • 60 mg subcutaneous injection in the upper arm, upper thigh, or abdomen by a healthcare professional
  • Pre-existing hypocalcemia must be corrected prior to initiating therapy with Prolia®. Adequately supplement all patients with calcium and vitamin D
  • Multiple vertebral fractures have been reported following Prolia® discontinuation
Dosing